The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia

@article{Kuendgen2006TheHD,
  title={The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia},
  author={A. Kuendgen and Mathias Schmid and R. P. Schlenk and S. Knipp and B. Hildebrandt and C. Steidl and U. Germing and R. Haas and H. Dōhner and N. Gattermann},
  journal={Cancer},
  year={2006},
  volume={106}
}
  • A. Kuendgen, Mathias Schmid, +7 authors N. Gattermann
  • Published 2006
  • Medicine
  • Cancer
    • Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all‐trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. 
    View on Wiley
    onlinelibrary.wiley.com
    218 Citations
    Highly Influencial Citations
    10
    Background Citations
    58
    Methods Citations
    10
    Results Citations
    5
    218 Citations
    Citation Type

    Citation Type

    Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
    • 78
    • PDF
    Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
    • 41
    • PDF
    Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
    • 42
    • PDF
    Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
    • 52
    Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
    • 2
    Valproic acid for the treatment of myeloid malignancies
    • 52
    Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
    • 77
    • Highly Influenced
    Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies
    • 21
    Valproic Acid and All-Trans Retinoic Acid: Meta-Analysis of a Palliative Treatment Regimen in AML and MDS Patients
    • 31
    Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
    • 130
    • PDF

    References

    SHOWING 1-10 OF 59 REFERENCES
    Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
    • 1,615
    • PDF
    Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
    • 386
    • PDF
    Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
    • 246
    • PDF
    Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    • 243
    • PDF
    Histone deacetylases as therapeutic targets in hematologic malignancies.
    • 120
    Histone deacetylase inhibitors in cancer treatment.
    • 177
    Histone deacetylase inhibitors in cancer treatment.
    • 262
    The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
    • 461
    Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen*
    • 1,525
    • PDF
    Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    • 212
    • Highly Influential
    • PDF